Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
about
Management of HBV and HBV/HDV-Associated Liver CirrhosisTherapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus InfectionInhibitor-Based Therapeutics for Treatment of Viral HepatitisTipifarnib prevents development of hypoxia-induced pulmonary hypertension.Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.Hepatitis Delta Virus Detected in Salivary Glands of Sjögren's Syndrome Patients and Recapitulates a Sjögren's Syndrome-Like Phenotype in Vivo.Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection.Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.The adventure of delta.Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Treatment of Delta Hepatitis: Today and in the Future - A review.Noninvasive markers for staging fibrosis in chronic delta hepatitis.Exploring the biochemistry of the prenylome and its role in disease through proteomics: progress and potential.Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen.Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis.Hepatitis delta: virological and clinical aspects.Investigational drugs in development for Hepatitis D.[Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E].Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification.First international external quality assessment for hepatitis delta virus RNA quantification in plasma.Recent advances in managing hepatitis DGenetic Diversity and Worldwide Distribution of the Deltavirus Genus: a Study of 2,152 Clinical Strains.Hepatitis delta virus infection in a large cohort of chronic hepatitis B patients in Ethiopia.Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.Global strategies are required to cure and eliminate HBV infection.Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.Emerging Therapeutic Targets for Hepatitis Delta Virus Infection.Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus.Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.High prevalence of hepatitis delta virus in CameroonPlacental Ras Regulates Inflammation Associated with Maternal Obesity
P2860
Q26740323-DED95A12-CD82-4CBB-A2FB-A06E86FD3108Q26795919-D26CF4A3-19AB-42BD-8F2E-9295687D81BDQ28073697-E3297010-D488-4410-8A98-F2F5B7AEA4CFQ33614140-A571764F-74BF-4A78-8575-37F934D180F7Q33807794-74E621EB-442B-4DAB-AFC0-8B535097F382Q34047019-3C86C969-F475-4963-82B9-B9FC6E761069Q36065068-0E55A0A6-1A9A-43E8-A5B5-9FD5A45DB46DQ37540212-B3B37457-ECD8-4D3D-977F-E1221CFF113AQ38685615-5184FCD4-7E45-43CC-814A-32A34B50B189Q38755178-E9684DE8-1E5D-42BB-B3E5-F2F0AA027F63Q38769975-9DA4D862-86AC-4E26-BA6E-D40B0AA15A66Q39215794-42D336A2-A473-4C4E-8AE0-DF130238EA00Q39316007-73B7FC72-C7E6-4848-AD7A-5CFCF4A5B7F8Q39414876-2946CBDA-A627-4D6E-9ECC-B6594D545A54Q40040535-0F5301FD-7B8B-4D74-9678-D28319CD468CQ40042818-A87752E3-93EB-4814-921F-5E7CD7374CF8Q40113645-03A91EEF-3144-46D2-9716-B17DE877F90AQ40153413-8281FD9D-F4F8-4DB2-BFB8-4783F0463CAEQ40437975-D173C89F-A56F-41A7-AB6A-6227CCFF5CCFQ40496079-BF258819-E927-45E5-BCB1-4F7ACC8D3F5FQ41588940-E1931CDE-ADB4-4D78-A029-A2255C9FE4E0Q41921473-9D79B637-BF05-4B20-82F5-477766C59DC0Q41923818-006C5D97-BD13-437C-9EE0-C2B96E7F708BQ47239374-05C209EA-CE1E-4715-B5B0-0DB1F3CF6D02Q47590580-796B5F80-19F9-4AED-850D-A10FE2ECA416Q48860247-D8212723-00B7-4051-BDBA-2B8CDC0FA99EQ50190669-ECA09409-B15C-4001-81DA-9191F0B35306Q50347087-3DFD0D9B-C9EF-43F4-B5A0-35B6F1CB59FFQ52699080-40D40430-F28C-4B96-AD9F-594B14FCDDA8Q53818354-DBEB9F6C-8970-4824-BE55-09874267B156Q54254238-3F7C330D-EB82-4A3C-BC8E-DEBC35400126Q56930136-79D01E87-B27C-4E05-BB6D-1B3796458E6BQ58580715-1D0BE6C7-BB29-44F4-AE54-5FA4E2EED6B5
P2860
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Oral prenylation inhibition wi ...... ebo-controlled phase 2A trial.
@ast
Oral prenylation inhibition wi ...... ebo-controlled phase 2A trial.
@en
type
label
Oral prenylation inhibition wi ...... ebo-controlled phase 2A trial.
@ast
Oral prenylation inhibition wi ...... ebo-controlled phase 2A trial.
@en
prefLabel
Oral prenylation inhibition wi ...... ebo-controlled phase 2A trial.
@ast
Oral prenylation inhibition wi ...... ebo-controlled phase 2A trial.
@en
P2093
P2860
P1476
Oral prenylation inhibition wi ...... cebo-controlled phase 2A trial
@en
P2093
Christopher Koh
Cihan Yurdaydin
Erin F Wolff
Gitanjali Subramanya
Harel Dahari
Jeffrey S Glenn
Ma Ai Thanda Han
Mark A Winters
Onur Keskin
Peter Pinto
P2860
P304
P356
10.1016/S1473-3099(15)00074-2
P577
2015-07-16T00:00:00Z